

1c575 U.S. PTO
01/15/98



A

Docket #: PF-0182-1 DIV

"Express Mail" mailing label number EM 081 942 611 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box Sequence, Washington, D.C. 20231 on 1/15/98

By: [Signature]

Printed: WILLIAMSON

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)**

Assistant Commissioner for Patents

Box Sequence

Washington, D.C. 20231

Attn: Nashed, N.

Class: 435

Subclass: 189

Dear Sir:

This is a request for filing a **DIVISIONAL** application under 37 CFR 1.53(b) of pending prior application Serial No. **08/774,169**, filed on **December 26, 1996**, entitled: **NOVEL GUANOSINE MONOPHOSPHATE REDUCTASE**.

1. ☒ Enclosed is a copy of the prior application, U. S. Application Serial No. **08/774,169** filed **December 26, 1996**, including the oath or declaration as originally filed.
2. ☒ With regard to the requirement of 37 CFR 1.821(d) which requires that a copy of the Sequence Listing in computer readable form (CRF) be submitted, Applicants submit that the computer readable form of the "Sequence Listing" in the instant divisional application, is identical with that filed for Serial No. **08/774,169**, filed **December 26, 1996**, to which priority is claimed. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed with U.S. Application Serial No. **08/774,169** as the computer readable form for the instant divisional application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant divisional application.
3. ☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 was filed in prior application number 08/ and such status is still proper and desired (37 CFR 1.28(a)).
4. ☒ Cancel in this application original claims 2-10 and 20 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

5. X The inventor of the invention being claimed in this application is: Jennifer L. Hillman.
6. X In accordance with 37 CFR 1.63(d) a copy of the originally signed declaration showing applicant's signature as filed on May 16, 1997, is enclosed.
7. X Amend the specification by inserting before the first line the sentence: "This application is a divisional application of U.S. application serial number **08/774,169**, filed **December 26, 1996**."
8. X The filing fee is calculated below:

Claims	Number Filed	Minus	Number Extra	Other Than Small Entity Rate	Basic Fee
					\$700.00
Total Claims	10	-20	0	x \$22	\$ 0.00
Indep. Claims	5	-3	2	x \$82	\$164.00
Multiple Dependent Claim(s), if any				+ \$270	\$ 0.00

TOTAL FILING FEE \$ 954.00

9. ___ An extension of time in the above-named prior application has been requested and the fees therefor have been authorized in said application.
10. X Please charge Deposit Amount No. **09-0108** in the amount of **\$954.00**.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Account No. **09-0108**.

Duplicate copies of these papers are enclosed.

11. ___ New formal drawings are enclosed.
12. ___ Priority of foreign application number _____, filed on _____ in _____ is claimed under 35 U.S.C. 119.
13. X The prior application is assigned of record to Incyte Pharmaceuticals, Inc.
14. X A preliminary amendment is enclosed.
15. ___ Also enclosed: _____

16. X The power of attorney of the prior application is to:

LUCY J. BILLINGS REG. NO. 36,749
MICHAEL C. CERRONE REG. NO. 39,132

- a. X The power of attorney appears in the original papers in the prior application.
b. ____ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
c. X Address all future correspondence to: (May only be completed by applicant, or attorney or agent of record.)

INCYTE PHARMACEUTICALS, INC.
PATENT DEPARTMENT
3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555, Fax: (650) 845-4166

Date: 1/12/98

By: Lucy J. Billings
Lucy J. Billings
Reg. No. 36,749

- ____ Inventor(s)
____ Assignee of complete interest
X Attorney or agent of record
____ Filed under 37 CFR 1.34(a)
Registration number if acting under 37 CFR 1.34(a) _____

A NOVEL GUANOSINE MONOPHOSPHATE REDUCTASE

FIELD OF THE INVENTION

This invention relates to nucleic acid and amino acid sequences of a novel guanosine monophosphate reductase and to the use of these sequences in the diagnosis, prevention, and treatment of cancer, viral diseases, inflammatory diseases, and immunological disorders.

5

BACKGROUND OF THE INVENTION

Guanosine monophosphate reductase (GMPR) catalyzes the NADPH dependent reductive deamination of GMP to inosine monophosphate (IMP). GMPR is a member of the "salvage pathway" in nucleotide biosynthesis which serves to recycle nucleotides and bases back into biosynthetic pathways leading to the synthesis of ATP and GTP. ATP and GTP are the principle purine nucleotide precursors to DNA and RNA in cells, and they control various aspects of signal transduction and energy metabolism. IMP dehydrogenase (IMPD) is a key enzyme at the branch point in the biosynthetic pathway leading to the synthesis of both ATP and GTP. Therefore, by regulating the substrate pools of GMP and IMP, GMPR participates in the regulation of both ATP and GTP.

15

GMPR occurs in most organisms including man. The human GMPR is a tetrameric molecule estimated to be approximately 170 KDa in size that is made up of monomers of approximately 37KDa. Several variant alleles of the human GMPR gene have been found in the chromosome 6-linked locus of the gene. The N-terminal 54 amino acid sequence of GMPR is found to be virtually identical to that of the major subunit of another chromosome 6-linked gene, glucose-6-phosphate dehydrogenase (G6PD; Kanno, H. et al. (1989) Cell 58: 595-606). However, the catalytic activity of GMPR is found in the C-terminal portion of the molecule and differs significantly from that of the latter enzyme.

20

Inhibitors of purine nucleotide biosynthesis in general, and of GTP synthesis in particular, have long been employed as antiproliferative agents to treat cancer and viral

25

diseases. The antitumor agents, tiazofurin and 3-deazaguanosine, originally thought to act through inhibition of IMPD have subsequently been found to be inhibitors of GMPR as well (Streeter, D.G. and Robins, R.K. (1983) Biochem. Biophys. Res. Comm. 115(2): 544-50; Page, T. et al. (1985) Cancer Chemother. Pharmacol. 15: 59-62; Prajda, N. et al. (1993) Cancer Res. 53: 5982-6). Antiviral agents such as the antibiotic mycophenolic acid also target this portion of the purine biosynthetic pathway (Franklin, T.J. and Cook, J.M. (1969) Biochem. J. 113: 515-24).

The discovery of polynucleotides encoding guanosine monophosphate reductase, and the molecules themselves, provides a means to investigate the role of the enzyme in cell replication and cell proliferation and in diseases associated with these processes. Such molecules related to guanosine monophosphate reductase satisfy a need in the art by providing new diagnostic or therapeutic compositions useful in diagnosing and treating cancer, viral diseases, inflammatory diseases, and immunological disorders.

SUMMARY OF THE INVENTION

The present invention features a novel guanosine monophosphate reductase hereinafter designated HGMPR and characterized as having similarity to GMPR from *E. coli* (GI 473772) and human red blood cells (GI 544455).

Accordingly, the invention features a substantially purified HGMPR having the amino acid sequence shown in SEQ ID NO:1.

One aspect of the invention features isolated and substantially purified polynucleotides that encode HGMPR. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:2.

The invention also relates to a polynucleotide sequence comprising the complement of SEQ ID NO:2 or variants thereof. In addition, the invention features polynucleotide sequences which hybridize under stringent conditions to SEQ ID NO:2.

The invention additionally features nucleic acid sequences encoding polypeptides, oligonucleotides, peptide nucleic acids (PNA), fragments, portions or antisense molecules thereof, and expression vectors and host cells comprising polynucleotides that encode

HGMPR. The present invention also features antibodies which bind specifically to HGMPR, and pharmaceutical compositions comprising substantially purified HGMPR. The invention also features the use of agonists and antagonists of HGMPR.

BRIEF DESCRIPTION OF THE FIGURES

Figures 1A, 1B, and 1C show the amino acid sequence (SEQ ID NO:1) and nucleic acid sequence (SEQ ID NO:2) of HGMPR. The alignment was produced using MacDNASIS PRO™ software (Hitachi Software Engineering Co., Ltd., San Bruno, CA).

Figures 2A and 2B show the amino acid sequence alignments among HGMPR (SEQ ID NO:1), and guanosine monophosphate reductase from *E. coli* (GI 473772; SEQ ID NO:3), and human red cells (GI 544455; SEQ ID NO:4). The alignment was produced using the multisequence alignment program of DNASTAR™ software (DNASTAR Inc, Madison WI).

Figure 3 shows the hydrophobicity plots (MacDNASIS PRO software) for HGMPR (A; SEQ ID NO: 1), *E. coli* GMPR(B; SEQ ID NO:3), and human red cell GMPR (C; SEQ ID NO:4); the positive X axis reflects amino acid position, and the negative Y axis, hydrophobicity.

Figure 4 shows the northern analysis for SEQ ID NO:2. The northern analysis was produced electronically using LIFESEQ™ database (Incyte Pharmaceuticals, Inc., Palo Alto, CA).

DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise.

Thus, for example, reference to "a host cell" includes a plurality of such host cells, reference to the "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

"Nucleic acid sequence" as used herein refers to an oligonucleotide, nucleotide, or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. Similarly, "amino acid sequence" as used herein refers to an oligopeptide, peptide, polypeptide, or protein sequence, and fragments or portions thereof, and to naturally occurring or synthetic molecules.

Where "amino acid sequence" is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms, such as "polypeptide" or "protein" are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule.

"Peptide nucleic acid", as used herein, refers to a molecule which comprises an oligomer to which an amino acid residue, such as lysine, and an amino group have been added. These small molecules, also designated anti-gene agents, stop transcript elongation by binding to their complementary strand of nucleic acid (Nielsen, P.E. et al. (1993) Anticancer Drug Des. 8:53-63).

HGMPR, as used herein, refers to the amino acid sequences of substantially purified HGMPR obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic, or recombinant.

5 "Consensus", as used herein, refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, or which has been extended using XL-PCR™ (Perkin Elmer, Norwalk, CT) in the 5' and/or the 3' direction and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte clone using the GEL VIEW™ Fragment Assembly system (GCG, Madison, WI), or which has been both
10 extended and assembled.

A "variant" of HGMPR, as used herein, refers to an amino acid sequence that is altered by one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, e.g.,
15 replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

20 A "deletion", as used herein, refers to a change in either amino acid or nucleotide sequence in which one or more amino acid or nucleotide residues, respectively, are absent.

An "insertion" or "addition", as used herein, refers to a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid or nucleotide residues, respectively, as compared to the naturally occurring molecule.

25 A "substitution", as used herein, refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

The term "biologically active", as used herein, refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic

HGMPR, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The term "agonist", as used herein, refers to a molecule which, when bound to HGMPR, causes a change in HGMPR which modulates the activity of HGMPR. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to HGMPR.

The terms "antagonist" or "inhibitor", as used herein, refer to a molecule which, when bound to HGMPR, blocks or modulates the biological or immunological activity of HGMPR. Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to HGMPR.

The term "modulate", as used herein, refers to a change or an alteration in the biological activity of HGMPR. Modulation may be an increase or a decrease in protein activity, a change in binding characteristics, or any other change in the biological, functional or immunological properties of HGMPR.

The term "mimetic", as used herein, refers to a molecule, the structure of which is developed from knowledge of the structure of HGMPR or portions thereof and, as such, is able to effect some or all of the actions of [REF PROT]-like molecules.

The term "derivative", as used herein, refers to the chemical modification of a nucleic acid encoding HGMPR or the encoded HGMPR. Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative would encode a polypeptide which retains essential biological characteristics of the natural molecule.

The term "substantially purified", as used herein, refers to nucleic or amino acid sequences that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated.

"Amplification" as used herein refers to the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction (PCR) technologies well known in the art (Dieffenbach, C.W. and G.S. Dveksler (1995) PCR

Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, NY).

The term “hybridization”, as used herein, refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

The term “hybridization complex”, as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., membranes, filters, chips, pins or glass slides to which cells have been fixed for *in situ* hybridization).

The terms “complementary” or “complementarity”, as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base pairing. For example, for the sequence “A-G-T” binds to the complementary sequence “T-C-A”. Complementarity between two single-stranded molecules may be “partial”, in which only some of the nucleic acids bind, or it may be complete when total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands.

The term “homology”, as used herein, refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity). A partially complementary sequence is one that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid; it is referred to using the functional term “substantially homologous.” The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a

completely homologous sequence or probe to the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity); in the absence of non-specific binding, the probe will not hybridize to the second non-complementary target sequence.

As known in the art, numerous equivalent conditions may be employed to comprise either low or high stringency conditions. Factors such as the length and nature (DNA, RNA, base composition) of the sequence, nature of the target (DNA, RNA, base composition, presence in solution or immobilization, etc.), and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate and/or polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions.

The term "stringent conditions", as used herein, is the "stringency" which occurs within a range from about $T_m - 5^\circ\text{C}$ (5°C below the melting temperature (T_m) of the probe) to about 20°C to 25°C below T_m . As will be understood by those of skill in the art, the stringency of hybridization may be altered in order to identify or detect identical or related polynucleotide sequences.

The term "antisense", as used herein, refers to nucleotide sequences which are complementary to a specific DNA or RNA sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. Antisense molecules may be produced by any method, including synthesis by ligating the gene(s) of interest in a reverse orientation to a viral promoter which permits the synthesis of a complementary strand. Once introduced into a cell, this transcribed strand combines with natural sequences produced by the cell to form duplexes. These duplexes then block either the further transcription or translation. In this manner, mutant phenotypes may be generated. The designation "negative" is sometimes used in reference to the antisense strand, and "positive" is sometimes used in reference to the sense strand.

The term "portion", as used herein, with regard to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from four amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein "comprising at least a portion of the amino acid sequence of SEQ ID NO:1" encompasses the full-length human HGMPR and fragments thereof.

"Transformation", as defined herein, describes a process by which exogenous DNA enters and changes a recipient cell. It may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the host cell being transformed and may include, but is not limited to, viral infection, electroporation, lipofection, and particle bombardment. Such "transformed" cells include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome. They also include cells which transiently express the inserted DNA or RNA for limited periods of time.

The term "antigenic determinant", as used herein, refers to that portion of a molecule that makes contact with a particular antibody (i.e., an epitope). When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The terms "specific binding" or "specifically binding", as used herein, in reference to the interaction of an antibody and a protein or peptide, mean that the interaction is dependent upon the presence of a particular structure (i.e., the antigenic determinant or epitope) on the protein; in other words, the antibody is recognizing and binding to a specific protein structure rather than to proteins in general. For example, if an antibody is specific for epitope "A", the presence of a protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.

The term "sample", as used herein, is used in its broadest sense. A biological sample suspected of containing nucleic acid encoding HGMPR or fragments thereof may comprise a cell, chromosomes isolated from a cell (e.g., a spread of metaphase chromosomes), genomic DNA (in solution or bound to a solid support such as for Southern analysis), RNA (in solution or bound to a solid support such as for northern analysis), cDNA (in solution or bound to a solid support), an extract from cells or a tissue, and the like.

The term "correlates with expression of a polynucleotide", as used herein, indicates that the detection of the presence of ribonucleic acid that is similar to SEQ ID NO:2 by northern analysis is indicative of the presence of mRNA encoding HGMPR in a sample and thereby correlates with expression of the transcript from the polynucleotide encoding the protein.

"Alterations" in the polynucleotide of SEQ ID NO: 2, as used herein, comprise any alteration in the sequence of polynucleotides encoding HGMPR including deletions, insertions, and point mutations that may be detected using hybridization assays. Included within this definition is the detection of alterations to the genomic DNA sequence which encodes HGMPR (e.g., by alterations in the pattern of restriction fragment length polymorphisms capable of hybridizing to SEQ ID NO:2), the inability of a selected fragment of SEQ ID NO: 2 to hybridize to a sample of genomic DNA (e.g., using allele-specific oligonucleotide probes), and improper or unexpected hybridization, such as hybridization to a locus other than the normal chromosomal locus for the polynucleotide sequence encoding HGMPR (e.g., using fluorescent *in situ* hybridization [FISH] to metaphase chromosomes spreads).

As used herein, the term "antibody" refers to intact molecules as well as fragments thereof, such as Fa, F(ab')₂, and Fv, which are capable of binding the epitopic determinant. Antibodies that bind HGMPR polypeptides can be prepared using intact polypeptides or fragments containing small peptides of interest as the immunizing antigen. The polypeptide or peptide used to immunize an animal can be derived from the transition of RNA or synthesized chemically, and can be conjugated to a carrier protein, if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin and

thyroglobulin. The coupled peptide is then used to immunize the animal (e.g., a mouse, a rat, or a rabbit).

The term "humanized antibody", as used herein, refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability.

THE INVENTION

The invention is based on the discovery of a novel human guanosine monophosphate reductase, (HGMPR), the polynucleotides encoding HGMPR, and the use of these compositions for the diagnosis, prevention, or treatment of cancer, viral diseases, inflammatory diseases, and immunological disorders.

Nucleic acids encoding the human HGMPR of the present invention were first identified in Incyte Clone 569141 from the macrophage cDNA library (MMLR3DT01) through a computer-generated search for amino acid alignments. A consensus sequence, SEQ ID NO:1, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 989/ U937NOT01, 43480/ TBLYNOT01, 256710/ HNT2RAT01, 297670/ HIPONOT01, 569141/ MMLR3DT01, 971292/ MUSCNOT02, 1458673/ COLNFET02, 1729347/ BRSTTUT08, and 1723868/ PROSNOT14.

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:1, as shown in Fig. 1A, 1B, and 1C. HGMPR is 366 amino acids in length and has cysteine residues representing potential intramolecular cysteine-cysteine disulfide bridging sites at C86, C113, C145, C204, C223, C240, and C334. As shown in Fig. 2A and 2B, HGMPR has chemical and structural homology with a GMPR from *E. coli* (GI 473772; SEQ ID NO:3) and human red blood cells (GI 544455; SEQ ID NO:4). In particular, HGMPR shares 72% overall identity with the *E. coli* GMPR, and 77% identity with the human GMPR. The most significant difference between HGMPR and the two GMPRs is the presence of an N-terminal sequence in HGMPR that is not present in the other two GMPR and may represent a novel signal sequence targeting HGMPR to different tissues. Six of the seven cysteine residues in HGMPR are shared by one or both of the two

GMMPs. As illustrated by Fig. 3A, 3B, and 3C, HGMPR and the GMMPs from *E. coli* and human have rather similar hydrophobicity plots. Northern analysis (Fig. 4), together with the libraries mentioned above, indicates that partial transcripts of the nucleic acid sequence encoding HGMPR are prominent in various cancerous tissues (prostate, brain, breast, and blood), and cells associated with inflammatory diseases and the immune response (mast cells, monocytes, macrophages, lymphocytes, and endothelial cells).

The invention also encompasses HGMPR variants. A preferred HGMPR variant is one having at least 80%, and more preferably 90%, amino acid sequence similarity to the HGMPR amino acid sequence (SEQ ID NO:1). A most preferred HGMPR variant is one having at least 95% amino acid sequence similarity to SEQ ID NO:1.

The invention also encompasses polynucleotides which encode HGMPR. Accordingly, any nucleic acid sequence which encodes the amino acid sequence of HGMPR can be used to generate recombinant molecules which express HGMPR. In a particular embodiment, the invention encompasses the polynucleotide comprising the nucleic acid sequence of SEQ ID NO:2 as shown in Fig. 1.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding HGMPR, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring HGMPR, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode HGMPR and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring HGMPR under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding HGMPR or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which

particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding HGMPR and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences, or portions thereof, which encode HGMPR and its derivatives, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents that are well known in the art at the time of the filing of this application. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding HGMPR or any portion thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed nucleotide sequences, and in particular, those shown in SEQ ID NO:2, under various conditions of stringency. Hybridization conditions are based on the melting temperature (T_m) of the nucleic acid binding complex or probe, as taught in Wahl, G.M. and S.L. Berger (1987; *Methods Enzymol.* 152:399-407) and Kimmel, A.R. (1987; *Methods Enzymol.* 152:507-511), and may be used at a defined stringency.

Altered nucleic acid sequences encoding HGMPR which are encompassed by the invention include deletions, insertions, or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent HGMPR. The encoded protein may also contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent HGMPR. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of HGMPR is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid; positively charged amino acids may include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine; glycine and alanine; asparagine and glutamine; serine and threonine; phenylalanine and tyrosine.

Also included within the scope of the present invention are alleles of the genes encoding HGMPR. As used herein, an "allele" or "allelic sequence" is an alternative form of the gene which may result from at least one mutation in the nucleic acid sequence. Alleles may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

Methods for DNA sequencing which are well known and generally available in the art may be used to practice any embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp, Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of recombinant polymerases and proofreading exonucleases such as the ELONGASE Amplification System marketed by Gibco BRL (Gaithersburg, MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI 377 DNA sequencers (Perkin Elmer).

The nucleic acid sequences encoding HGMPR may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed, "restriction-site" PCR, uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). In particular, genomic DNA is first amplified in the presence of primer to linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186). The primers

may be designed using OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, MN), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) PCR Methods Appl. 1:111-119). In this method, multiple restriction enzyme digestions and ligations may also be used to place an engineered double-stranded sequence into an unknown portion of the DNA molecule before performing PCR.

Another method which may be used to retrieve unknown sequences is that of Parker, J.D. et al. (1991; Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinder™ libraries to walk in genomic DNA (Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into the 5' and 3' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity may be converted to electrical signal using appropriate software (e.g. Genotyper™ and Sequence Navigator™, Perkin Elmer) and the entire process from loading of samples to

computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode HGMPR, or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct expression of HGMPR in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express HGMPR.

As will be understood by those of skill in the art, it may be advantageous to produce HGMPR-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter HGMPR encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, or introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding HGMPR may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of HGMPR activity, it may be useful to encode a chimeric HGMPR protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the HGMPR encoding sequence and the heterologous protein

sequence, so that HGMPR may be cleaved and purified away from the heterologous moiety.

In another embodiment, sequences encoding HGMPR may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of HGMPR, or a portion thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J.Y. et al. (1995) Science 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer).

The newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co., New York, NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; Creighton, supra). Additionally, the amino acid sequence of HGMPR, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a biologically active HGMPR, the nucleotide sequences encoding HGMPR or functional equivalents, may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding HGMPR and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, and Ausubel, F.M. et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY.

A variety of expression vector/host systems may be utilized to contain and express

sequences encoding HGMPR. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

The "control elements" or "regulatory sequences" are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript® phagemid (Stratagene, LaJolla, CA) or pSport1™ plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding HGMPR, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for HGMPR. For example, when large quantities of HGMPR are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional *E. coli* cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding HGMPR may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem.

264:5503-5509); and the like. pGEX vectors (Promega, Madison, WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, Saccharomyces cerevisiae, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) *Methods Enzymol.* 153:516-544.

In cases where plant expression vectors are used, the expression of sequences encoding HGMPR may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311).

Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L.E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, NY; pp. 191-196).

An insect system may also be used to express HGMPR. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequences encoding HGMPR may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of HGMPR will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, S.

frugiperda cells or Trichoplusia larvae in which HGMPR may be expressed (Engelhard, E.K. et al. (1994) Proc. Nat. Acad. Sci. 91:3224-3227).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding HGMPR may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing HGMPR in infected host cells (Logan, J. and Shenk, T. (1984) Proc. Natl. Acad. Sci. 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding HGMPR. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding HGMPR, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, HEK293, and WI38, which have specific cellular machinery and characteristic mechanisms for such

post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express HGMPR may be transformed using
 5 expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of
 10 cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M.
 15 et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) Cell 22:817-23) genes which can be employed in tk⁻ or aprt⁻ cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and
 20 G-418 (Colbere-Garapin, F. et al (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-51).
 25 Recently, the use of visible markers has gained popularity with such markers as anthocyanins, β glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C.A. et al. (1995) Methods Mol. Biol. 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding HGMPR is inserted within a marker gene sequence, recombinant cells containing sequences encoding HGMPR can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding HGMPR under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells which contain the nucleic acid sequence encoding HGMPR and express HGMPR may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

The presence of polynucleotide sequences encoding HGMPR can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or portions or fragments of polynucleotides encoding HGMPR. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the sequences encoding HGMPR to detect transformants containing DNA or RNA encoding HGMPR. As used herein "oligonucleotides" or "oligomers" refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides, which can be used as a probe or amplifier.

A variety of protocols for detecting and measuring the expression of HGMPR, using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on HGMPR is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St Paul, MN) and Maddox, D.E. et al. (1983; J. Exp. Med.

158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding HGMPR include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding HGMPR, or any portions thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH). Suitable reporter molecules or labels, which may be used, include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding HGMPR may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode HGMPR may be designed to contain signal sequences which direct secretion of HGMPR through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may be used to join sequences encoding HGMPR to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and HGMPR may be used to facilitate purification. One

such expression vector provides for expression of a fusion protein containing HGMPR and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMIAC (immobilized metal ion affinity chromatography as described in Porath, J. et al. (1992, Prot. Exp. Purif. 3: 263-281) while the enterokinase cleavage site provides a means for purifying HGMPR from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. et al. (1993; DNA Cell Biol. 12:441-453).

In addition to recombinant production, fragments of HGMPR may be produced by direct peptide synthesis using solid-phase techniques Merrifield J. (1963) J. Am. Chem. Soc. 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Various fragments of HGMPR may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

THERAPEUTICS

HGMPR bears chemical and structural homology to GMPRs from *E. coli* (SEQ ID NO:3) and man (SEQ ID NO:4). Furthermore, GMPRs are known to play a role in various conditions involving a proliferative cell state such as cancer, viral diseases, inflammation, or the immune response. Based on these facts, and the expression of HGMPR in various normal and tumor tissues and in tissues involved in inflammation and the immune response, HGMPR is believed to play a role in cancer, viral diseases, inflammatory diseases, and immunological disorders.

Therefore, in one embodiment, a vector expressing antisense of the polynucleotide encoding HGMPR may be administered to a subject to treat or prevent cancer. Cancers may include, but are not limited to, cancers of the prostate, brain, breast, colon, heart, and leukemias.

In another embodiment, a vector expressing antisense of the polynucleotide encoding HGMPR may be administered to a subject to treat or prevent viral diseases. Viral diseases

may include, but are not limited to herpes simplex type I and type II, influenza, rhinovirus, cytomegalovirus, hepatitis, and human immunodeficiency virus (AIDS).

In another embodiment, a vector expressing antisense of the polynucleotide encoding HGMPR may be administered to a subject to treat or prevent inflammatory diseases and immunological disorders, which may include, but are not limited to conditions such as anemias, asthma, systemic lupus, myasthenia gravis, diabetes mellitus, autoimmune thyroiditis, pancreatitis, ulcerative colitis, osteoporosis, glomerulonephritis; rheumatoid and osteoarthritis; and scleroderma.

In another embodiment, antagonists or inhibitors of HGMPR may be administered to a subject to treat or prevent cancers described above.

In another embodiment, antagonists or inhibitors of HGMPR may be administered to a subject to treat or prevent viral diseases described above.

In another embodiment, antagonists or inhibitors of HGMPR may be administered to a subject to treat or prevent inflammatory diseases and immunological disorders described above.

Antibodies which are specific for HGMPR may be used directly as an antagonist, or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express HGMPR.

In other embodiments, any of the therapeutic proteins, antagonists, antibodies, agonists, antisense sequences or vectors described above may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

Antagonists or inhibitors of HGMPR may be produced using methods which are generally known in the art. In particular, purified HGMPR may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically

bind HGMPR.

Antibodies to HGMPR may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, and fragments produced by a Fab expression library.

- 5 Neutralizing antibodies, (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with HGMPR or any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

15 It is preferred that the peptides, fragments, or oligopeptides used to induce antibodies to HGMPR have an amino acid sequence consisting of at least five amino acids, and more preferably at least 10 amino acids. It is also preferable that they are identical to a portion of the amino acid sequence of the natural protein, and they may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of HGMPR amino acids
20 may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule.

Monoclonal antibodies to HGMPR may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma
25 technique, and the EBV-hybridoma technique (Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. 80:2026-2030; Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120).

In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with

appropriate antigen specificity and biological activity can be used (Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; Takeda, S. et al. (1985) Nature 314:452-454). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce HGMPR-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton D.R. (1991) Proc. Natl. Acad. Sci. 88:11120-3).

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837; Winter, G. et al. (1991) Nature 349:293-299).

Antibody fragments which contain specific binding sites for HGMPR may also be generated. For example, such fragments include, but are not limited to, the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse, W.D. et al. (1989) Science 254:1275-1281).

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between HGMPR and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering HGMPR epitopes is preferred, but a competitive binding assay may also be employed (Maddox, supra).

In another embodiment of the invention, the polynucleotides encoding HGMPR, or any fragment thereof, or antisense molecules, may be used for therapeutic purposes. In one

aspect, antisense to the polynucleotide encoding HGMPR may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding HGMPR. Thus, antisense molecules may be used to modulate HGMPR activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligomers or larger fragments, can be designed from various locations along the coding or control regions of sequences encoding HGMPR.

Expression vectors derived from retro viruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct recombinant vectors which will express antisense molecules complementary to the polynucleotides of the gene encoding HGMPR. These techniques are described both in Sambrook et al. (supra) and in Ausubel et al. (supra).

Genes encoding HGMPR can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide or fragment thereof which encodes HGMPR. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA, or PNA, to the control regions of the gene encoding HGMPR, i.e., the promoters, enhancers, and introns. Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. et al. (1994) In: Huber, B.E. and B.I. Carr, Molecular and

Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples which may be used include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding HGMPR.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Antisense molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding HGMPR. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in

the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection and by liposome injections may be achieved using methods which are well known in the art.

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of HGMPR, antibodies to HGMPR, mimetics, agonists, antagonists, or inhibitors of HGMPR. The compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be

found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated

in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of HGMPR, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either

in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

5 A therapeutically effective dose refers to that amount of active ingredient, for example HGMPR or fragments thereof, antibodies of HGMPR, agonists, antagonists or inhibitors of HGMPR, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50
10 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of
15 circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide
20 sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once
25 every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for

proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

5 In another embodiment, antibodies which specifically bind HGMPR may be used for the diagnosis of conditions or diseases characterized by expression of HGMPR, or in assays to monitor patients being treated with HGMPR, agonists, antagonists or inhibitors. The antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for HGMPR include methods which
10 utilize the antibody and a label to detect HGMPR in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules which are known in the art may be used, several of which are described above.

15 A variety of protocols including ELISA, RIA, and FACS for measuring HGMPR are known in the art and provide a basis for diagnosing altered or abnormal levels of HGMPR expression. Normal or standard values for HGMPR expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to HGMPR under conditions suitable for complex formation. The amount of
20 standard complex formation may be quantified by various methods, but preferably by photometric means. Quantities of HGMPR expressed in subject, control and disease, samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

25 In another embodiment of the invention, the polynucleotides encoding HGMPR may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, antisense RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of HGMPR may be correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of HGMPR, and to

monitor regulation of HGMPR levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding HGMPR or closely related molecules, may be used to identify nucleic acid sequences which encode HGMPR. The specificity of the probe, whether it is made from a highly specific region, e.g., 10 unique nucleotides in the 5' regulatory region, or a less specific region, e.g., especially in the 3' coding region, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occurring sequences encoding HGMPR, alleles, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the HGMPR encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and derived from the nucleotide sequence of SEQ ID NO:2 or from genomic sequence including promoter, enhancer elements, and introns of the naturally occurring HGMPR.

Means for producing specific hybridization probes for DNAs encoding HGMPR include the cloning of nucleic acid sequences encoding HGMPR or HGMPR derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, radionuclides such as ³²P or ³⁵S, or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding HGMPR may be used for the diagnosis of conditions or diseases which are associated with expression of HGMPR. Examples of such conditions or diseases include cancers of the prostate, brain, breast, colon, heart, and leukemias, viral diseases such as simplex type I and type II, influenza, rhinovirus, cytomegalovirus, hepatitis, and human immunodeficiency virus (AIDS), and immunological disorders such as anemias, asthma, systemic lupus, and myasthenia gravis, diabetes mellitus, osteoporosis, glomerulonephritis; rheumatoid and osteoarthritis; and scleroderma. The

polynucleotide sequences encoding HGMPR may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; or in dip stick, pin, ELISA or chip assays utilizing fluids or tissues from patient biopsies to detect altered HGMPR expression. Such qualitative or quantitative methods are well known in the art.

5 In a particular aspect, the nucleotide sequences encoding HGMPR may be useful in assays that detect activation or induction of various cancers, particularly those mentioned above. The nucleotide sequences encoding HGMPR may be labeled by standard methods, and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is
10 washed and the signal is quantitated and compared with a standard value. If the amount of signal in the biopsied or extracted sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding HGMPR in the sample indicates the presence of the associated disease. Such assays may also be used to
15 evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of disease associated with expression of HGMPR, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either
20 animal or human, with a sequence, or a fragment thereof, which encodes HGMPR, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with those from an experiment where a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from
25 samples from patients who are symptomatic for disease. Deviation between standard and subject values is used to establish the presence of disease.

Once disease is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to evaluate whether the level of expression in the patient begins to approximate that which is observed in the normal patient. The results obtained

from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding HGMPR may involve the use of PCR. Such oligomers may be chemically synthesized, generated enzymatically, or produced from a recombinant source. Oligomers will preferably consist of two nucleotide sequences, one with sense orientation ($5' \rightarrow 3'$) and another with antisense ($3' \leftarrow 5'$), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of HGMPR include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated (Melby, P.C. et al. (1993) *J. Immunol. Methods*, 159:235-244; Duplaa, C. et al. (1993) *Anal. Biochem.* 229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In another embodiment of the invention, the nucleic acid sequences which encode HGMPR may also be used to generate hybridization probes which are useful for mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. Such techniques include FISH, FACS, or artificial chromosome constructions, such as yeast artificial chromosomes, bacterial artificial chromosomes, bacterial P1 constructions or single

chromosome cDNA libraries as reviewed in Price, C.M. (1993) *Blood Rev.* 7:127-134, and Trask, B.J. (1991) *Trends Genet.* 7:149-154.

FISH (as described in Verma et al. (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, NY) may be correlated with other physical chromosome mapping techniques and genetic map data. Examples of genetic map data can be found in the 1994 Genome Issue of *Science* (265:1981f). Correlation between the location of the gene encoding HGMPR on a physical chromosomal map and a specific disease, or predisposition to a specific disease, may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier, or affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti, R.A. et al. (1988) *Nature* 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

In another embodiment of the invention, HGMPR, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes, between HGMPR and the agent being tested, may be measured.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, as applied to HGMPR large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with HGMPR, or fragments thereof, and washed. Bound HGMPR is then detected by methods well known in the art. Purified HGMPR can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding HGMPR specifically compete with a test compound for binding HGMPR. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with HGMPR.

In additional embodiments, the nucleotide sequences which encode HGMPR may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

EXAMPLES

I MMLR3DT01 cDNA Library Construction

The MMLR3DT01 was constructed from normal peripheral blood macrophages obtained from two 24 year old, Caucasian males. This library represents a mixture of allogeneically stimulated human macrophage populations obtained from Ficoll/Hypaque purified buffy coats. The cells from the two different donors (not typed for HLA alleles) were incubated at a density of $1 \times 10^6/\text{ml}$ for 72 hours in DME containing 10% human serum.

After incubation, macrophages mostly adhered to the plastic surface of the petri dish, whereas most other cell types, B and T lymphocytes, remained in solution. The DME was

decanted from the wells, and the wells were washed with phosphate buffered saline (PBS). Macrophages were released from the plastic surface by gently scraping the petri dishes in PBS/1 mM EDTA. Macrophages were lysed immediately in buffer containing guanidinium isothiocyanate.

The lysate was extracted twice with a mixture of acid phenol pH 4.0 and centrifuged over a CsCl cushion using an Beckman SW28 rotor in a L8-70M Ultracentrifuge (Beckman Instruments). The RNA was precipitated using 0.3 M sodium acetate and 2.5 volumes of ethanol, resuspended in water and DNase treated for 15 min at 37°C. It must be noted that some contaminating T and B lymphocytes may have been present.

The RNA was used in the SuperScript Plasmid System for cDNA Synthesis and Plasmid Cloning (catalogue #18248-013; Gibco BRL, Gaithersburg MD) with the recommended protocol. cDNAs were fractionated on a Sepharose CL4B column (catalog #275105, Pharmacia), and those cDNAs exceeding 400 bp were ligated into pSport I. The plasmid was transformed into chemically competent DH5 α host cells (Gibco BRL).

II Isolation and Sequencing of cDNA Clones

Plasmid DNA was released from the cells and purified using the Miniprep Kit (Catalogue # 77468; Advanced Genetic Technologies Corporation, Gaithersburg MD). This kit consists of a 96 well block with reagents for 960 purifications. The recommended protocol was employed except for the following changes: 1) the 96 wells were each filled with only 1 ml of sterile Terrific Broth (Catalog # 22711, LIFE TECHNOLOGIES™, Gaithersburg MD) with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) the bacteria were cultured for 24 hours after the wells were inoculated and then lysed with 60 μ l of lysis buffer; 3) a centrifugation step employing the Beckman GS-6R @2900 rpm for 5 min was performed before the contents of the block were added to the primary filter plate; and 4) the optional step of adding isopropanol to TRIS buffer was not routinely performed. After the last step in the protocol, samples were transferred to a Beckman 96-well block for storage.

The cDNAs were sequenced by the method of Sanger F and AR Coulson (1975; J Mol Biol 94:441f), using a Hamilton Micro Lab 2200 (Hamilton, Reno NV) in combination with

four Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown MA) and Applied Biosystems 377 or 373 DNA Sequencing Systems (Perkin Elmer) and reading frame was determined.

III Homology Searching of cDNA Clones and Their Deduced Proteins

Each cDNA was compared to sequences in GenBank using a search algorithm developed by Applied Biosystems and incorporated into the INHERIT™ 670 sequence analysis system. In this algorithm, Pattern Specification Language (TRW Inc, Los Angeles, CA) was used to determine regions of homology. The three parameters that determine how the sequence comparisons run were window size, window offset, and error tolerance. Using a combination of these three parameters, the DNA database was searched for sequences containing regions of homology to the query sequence, and the appropriate sequences were scored with an initial value. Subsequently, these homologous regions were examined using dot matrix homology plots to distinguish regions of homology from chance matches.

Smith-Waterman alignments were used to display the results of the homology search.

Peptide and protein sequence homologies were ascertained using the INHERIT- 670 sequence analysis system using the methods similar to those used in DNA sequence homologies. Pattern Specification Language and parameter windows were used to search protein databases for sequences containing regions of homology which were scored with an initial value. Dot-matrix homology plots were examined to distinguish regions of significant homology from chance matches.

BLAST, which stands for Basic Local Alignment Search Tool (Altschul, S.F. (1993) J. Mol. Evol. 36:290-300; Altschul et al. (1990) J. Mol. Biol. 215:403-410), was used to search for local sequence alignments. BLAST produces alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in determining exact matches or in identifying homologs. BLAST is useful for matches which do not contain gaps. The fundamental unit of BLAST algorithm output is the High-scoring Segment Pair (HSP).

An HSP consists of two sequence fragments of arbitrary but equal lengths whose

alignment is locally maximal and for which the alignment score meets or exceeds a threshold or cutoff score set by the user. The BLAST approach is to look for HSPs between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance. The parameter E establishes the statistically significant threshold for reporting database sequence matches. E is interpreted as the upper bound of the expected frequency of chance occurrence of an HSP (or set of HSPs) within the context of the entire database search. Any database sequence whose match satisfies E is reported in the program output.

IV Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook et al., supra).

Analogous computer techniques using BLAST (Altschul, S.F. 1993 and 1990, supra) are used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ™ database (Incyte Pharmaceuticals). This analysis is much faster than multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

The basis of the search is the product score which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1-2% error; and at 70, the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analysis are reported as a list of libraries in which the transcript encoding HGMPR occurs. Abundance and percent abundance are also reported.

Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library.

V Extension of HGMPR-Encoding Polynucleotides to Full Length or to Recover Regulatory Sequences

Full length HGMPR-encoding nucleic acid sequence (SEQ ID NO:2) is used to design oligonucleotide primers for extending a partial nucleotide sequence to full length or for obtaining 5' or 3', intron or other control sequences from genomic libraries. One primer is synthesized to initiate extension in the antisense direction (XLR) and the other is synthesized to extend sequence in the sense direction (XLF). Primers are used to facilitate the extension of the known sequence "outward" generating amplicons containing new, unknown nucleotide sequence for the region of interest. The initial primers are designed from the cDNA using OLIGO 4.06 (National Biosciences), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations is avoided.

The original, selected cDNA libraries, or a human genomic library are used to extend the sequence; the latter is most useful to obtain 5' upstream regions. If more extension is necessary or desired, additional sets of primers are designed to further extend the known region.

By following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix, high fidelity amplification is obtained. Beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, PCR is performed using the Peltier Thermal Cycler (PTC200; M.J. Research, Watertown, MA) and the following parameters:

Step 1	94° C for 1 min (initial denaturation)
Step 2	65° C for 1 min
Step 3	68° C for 6 min
Step 4	94° C for 15 sec

Step 5	65° C for 1 min
Step 6	68° C for 7 min
Step 7	Repeat step 4-6 for 15 additional cycles
Step 8	94° C for 15 sec
Step 9	65° C for 1 min
Step 10	68° C for 7:15 min
Step 11	Repeat step 8-10 for 12 cycles
Step 12	72° C for 8 min
Step 13	4° C (and holding)

A 5-10 μ l aliquot of the reaction mixture is analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products are selected and removed from the gel. Further purification involves using a commercial gel extraction method such as QIAquick™ (QIAGEN Inc., Chatsworth, CA). After recovery of the DNA, Klenow enzyme is used to trim single-stranded, nucleotide overhangs creating blunt ends which facilitate religation and cloning.

After ethanol precipitation, the products are redissolved in 13 μ l of ligation buffer, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase are added, and the mixture is incubated at room temperature for 2-3 hours or overnight at 16° C. Competent *E. coli* cells (in 40 μ l of appropriate media) are transformed with 3 μ l of ligation mixture and cultured in 80 μ l of SOC medium (Sambrook et al., supra). After incubation for one hour at 37° C, the whole transformation mixture is plated on Luria Bertani (LB)-agar (Sambrook et al., supra) containing 2x Carb. The following day, several colonies are randomly picked from each plate and cultured in 150 μ l of liquid LB/2x Carb medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture is transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 μ l of each sample is transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction are added to each well. Amplification is performed using the following conditions:

	Step 1	94° C for 60 sec
	Step 2	94° C for 20 sec
	Step 3	55° C for 30 sec
	Step 4	72° C for 90 sec
5	Step 5	Repeat steps 2-4 for an additional 29 cycles
	Step 6	72° C for 180 sec
	Step 7	4° C (and holding)

Aliquots of the PCR reactions are run on agarose gels together with molecular weight
 10 markers. The sizes of the PCR products are compared to the original partial cDNAs, and
 appropriate clones are selected, ligated into plasmid, and sequenced.

VI Labeling and Use of Hybridization Probes

Hybridization probes derived from SEQ ID NO:2 are employed to screen cDNAs,
 15 genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about
 20 base-pairs, is specifically described, essentially the same procedure is used with larger
 cDNA fragments. Oligonucleotides are designed using state-of-the-art software such as
 OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and
 250 μ Ci of [γ - 32 P] adenosine triphosphate (Amersham) and T4 polynucleotide kinase
 20 (DuPont NEN®, Boston, MA). The labeled oligonucleotides are substantially purified with
 Sephadex G-25 superfine resin column (Pharmacia & Upjohn). A portion containing 10^7
 counts per minute of each of the sense and antisense oligonucleotides is used in a typical
 membrane based hybridization analysis of human genomic DNA digested with one of the
 following endonucleases (Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II; DuPont NEN®).

The DNA from each digest is fractionated on a 0.7 percent agarose gel and
 transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham, NH).
 Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are
 sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x
 saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT ART™ film (Kodak,
 30 Rochester, NY) is exposed to the blots in a Phosphorimager cassette (Molecular Dynamics,
 Sunnyvale, CA) for several hours, hybridization patterns are compared visually.

VII Antisense Molecules

Antisense molecules to the HGMPR-encoding sequence, or any part thereof, is used to inhibit *in vivo* or *in vitro* expression of naturally occurring HGMPR. Although use of antisense oligonucleotides, comprising about 20 base-pairs, is specifically described, essentially the same procedure is used with larger cDNA fragments. An oligonucleotide based on the coding sequences of HGMPR, as shown in Fig. 1, is used to inhibit expression of naturally occurring HGMPR. The complementary oligonucleotide is designed from the most unique 5' sequence as shown in Fig. 1 and used either to inhibit transcription by preventing promoter binding to the upstream nontranslated sequence or translation of an HGMPR-encoding transcript by preventing the ribosome from binding. Using an appropriate portion of the signal and 5' sequence of SEQ ID NO:2, an effective antisense oligonucleotide includes any 15-20 nucleotides spanning the region which translates into the signal or 5' coding sequence of the polypeptide as shown in Fig. 1.

VIII Expression of HGMPR

Expression of HGMPR is accomplished by subcloning the cDNAs into appropriate vectors and transforming the vectors into host cells. In this case, the cloning vector, pSport, previously used for the generation of the cDNA library is used to express HGMPR in *E. coli*. Upstream of the cloning site, this vector contains a promoter for β -galactosidase, followed by sequence containing the amino-terminal Met, and the subsequent seven residues of β -galactosidase. Immediately following these eight residues is a bacteriophage promoter useful for transcription and a linker containing a number of unique restriction sites.

Induction of an isolated, transformed bacterial strain with IPTG using standard methods produces a fusion protein which consists of the first eight residues of β -galactosidase, about 5 to 15 residues of linker, and the full length protein. The signal residues direct the secretion of HGMPR into the bacterial growth media which can be used directly in the following assay for activity.

IX Demonstration of HGMPR Activity

HGMPR activity is measured spectrophotometrically by the change in absorbance at 340nm due to the oxidation of the co-enzyme NADPH to NADP in the presence of the enzyme and GMP. The reaction mixture contains HGMPR, 3 mM GMP, 1 mM NADPH, 2 mM 2-mercaptoethanol, and 1 mM EDTA in a Tris-chloride buffer, pH 7.8. The reaction is carried out in a quartz cuvette at 37°C, and the change in absorbance at 340nm is followed using an ultraviolet spectrophotometer. The reaction is corrected for non-specific oxidation of NADPH in the absence of the substrate GMP. The rate of change of absorbance at 340nm is proportional to the activity of HGMPR in the assay.

X Production of HGMPR Specific Antibodies

HGMPR that is substantially purified using PAGE electrophoresis (Sambrook, supra), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols. The amino acid sequence deduced from SEQ ID NO:2 is analyzed using DNASTAR software (DNASTAR Inc) to determine regions of high immunogenicity and a corresponding oligopolypeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is described by Ausubel et al. (supra), and others.

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma, St. Louis, MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel et al., supra). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated, goat anti-rabbit IgG.

XI Purification of Naturally Occurring HGMPR Using Specific Antibodies

Naturally occurring or recombinant HGMPR is substantially purified by

immunoaffinity chromatography using antibodies specific for HGMPR. An immunoaffinity column is constructed by covalently coupling HGMPR antibody to an activated chromatographic resin, such as CnBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing HGMPR is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of HGMPR (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/HGMPR binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope, such as urea or thiocyanate ion), and HGMPR is collected.

XII Identification of Molecules Which Interact with HGMPR

HGMPR or biologically active fragments thereof are labeled with ^{125}I Bolton-Hunter reagent (Bolton et al. (1973) Biochem. J. 133: 529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled HGMPR, washed and any wells with labeled HGMPR complex are assayed. Data obtained using different concentrations of HGMPR are used to calculate values for the number, affinity, and association of HGMPR with the candidate molecules.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Hillman, Jennifer L.
- (ii) TITLE OF THE INVENTION: A NOVEL GUANOSINE MONOPHOSPHATE REDUCTASE
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
 - (B) STREET: 3174 Porter Drive
 - (C) CITY: Palo Alto
 - (D) STATE: CA
 - (E) COUNTRY: USA
 - (F) ZIP: 94304
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: To Be Assigned
 - (B) FILING DATE: Herewith
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Billings, Lucy J.
 - (B) REGISTRATION NUMBER: 36,749
 - (C) REFERENCE/DOCKET NUMBER: PF-0182 US
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 415-855-0555
 - (B) TELEFAX: 415-845-4166
 - (C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 366 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (vii) IMMEDIATE SOURCE:
 - (A) LIBRARY: Consensus
 - (B) CLONE: Consensus
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

Met Thr Cys Cys Leu Pro Ala Leu Arg Phe Ile Ala Thr Pro Arg Leu
1      5      10
Ser Ala Met Pro His Ile Asp Asn Asp Val Lys Leu Asp Phe Lys Asp
20     25     30
Val Leu Leu Arg Pro Lys Arg Ser Thr Leu Lys Ser Arg Ser Glu Val
35     40     45
Asp Leu Thr Arg Ser Phe Ser Phe Arg Asn Ser Lys Gln Thr Tyr Ser
50     55     60
Gly Val Pro Ile Ile Ala Ala Asn Met Asp Thr Val Gly Thr Phe Glu
65     70     75
Met Ala Lys Val Leu Cys Lys Phe Ser Leu Phe Thr Ala Val His Lys
85     90     95
His Tyr Ser Leu Val Gln Trp Gln Glu Phe Ala Gly Gln Asn Pro Asp
100    105   110
Cys Leu Glu His Leu Ala Ala Ser Ser Gly Thr Gly Ser Ser Asp Phe
115    120   125
Glu Gln Leu Glu Gln Ile Leu Glu Ala Ile Pro Gln Val Lys Tyr Ile
130    135   140
Cys Leu Asp Val Ala Asn Gly Tyr Ser Glu His Phe Val Glu Phe Val
145    150   155
Lys Asp Val Arg Lys Arg Phe Pro Gln His Thr Ile Met Ala Gly Asn
165    170   175
Val Val Thr Gly Glu Met Val Glu Glu Leu Ile Leu Ser Gly Ala Asp
180    185   190
Ile Ile Lys Val Gly Ile Gly Pro Gly Ser Val Cys Thr Thr Arg Lys
195    200   205
Lys Thr Gly Val Gly Tyr Pro Gln Leu Ser Ala Val Met Glu Cys Ala
210    215   220
Asp Ala Ala His Gly Leu Lys Gly His Ile Ile Ser Asp Gly Gly Cys
225    230   235
Ser Cys Pro Gly Asp Val Ala Lys Ala Phe Gly Ala Gly Ala Asp Phe
245    250   255
Val Met Leu Gly Gly Met Leu Ala Gly His Ser Glu Ser Gly Gly Glu
260    265   270
Leu Ile Glu Arg Asp Gly Lys Lys Tyr Lys Leu Phe Tyr Gly Met Ser
275    280   285
Ser Glu Met Ala Met Lys Lys Tyr Ala Gly Gly Val Ala Glu Tyr Arg
290    295   300
Ala Ser Glu Gly Lys Thr Val Glu Val Pro Phe Lys Gly Asp Val Glu
305    310   315
His Thr Ile Arg Asp Ile Leu Gly Gly Ile Arg Ser Thr Cys Thr Tyr
325    330   335
Val Gly Ala Ala Lys Leu Lys Glu Leu Ser Arg Arg Thr Thr Phe Ile
340    345   350
Arg Val Thr Gln Gln Val Asn Pro Ile Phe Ser Glu Ala Cys
355    360   365

```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1843 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: Consensus
- (B) CLONE: Consensus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CTAAATCAGC	CTCTTGCCCC	ATTGCTCTTT	GCAGGGGTAG	AAGAAGGAAG	TGTAGCGGGG	60
TAAGGAATGC	ACCGTCAGGG	TCTCTCACAA	CCCTTTCCTCC	GCTCTCCTCC	CCAACAAACA	120
GTACCTGGGA	TGGAGCCCTA	GGGTAATCGC	AGCCACGGGA	TGGGTCGAGG	TGACAGGCTT	180
CAGGGACCAC	ACTTCGGGCT	TTGCCCGACC	TTCACAACCT	TAAGCGAAGA	GAGGCCACCA	240
GCCGTAACAG	GGCGTTAAAG	CCCAGGGGAA	GATTGGTCTT	TATGACTTGC	TGCCTTCCAG	300
CCCTCAGATT	CATCGCTACC	CCGAGGCTAA	CGCCCATGCC	TCATATTGAC	AACGATGTGA	360
AACTGGACTT	CAAGGATGTC	CTTTTGAGGC	CCAAACGCAG	TACCCCTTAAG	TCTCGAAGTG	420
AGGTGGATCT	CACAAGATCC	TTTTCATTTT	GGAACCTCAA	GCAGACATAC	TCTGGGGTTC	480
CCATCATTGC	TGCCAATATG	GATACTGTGG	GCACCTTTGA	GATGGCCAAG	GTTCTCTGTA	540
AGTTTCTCTT	CTTCAGTGCT	GTCCTAAGC	ACTATAGCCT	CGTTCACTGG	CAAGAGTTTG	600
CTGGCCAGAA	TCCTGACTGT	CTTGAGCATC	TGGCTGCCAG	CTCAGGCACA	GGCTCTTCTG	660
ACTTTTGAGCA	GCTGGAACAG	ATCCTGGAAG	CTATTCCCCA	GGTGAAGTAT	ATATGCTCTG	720
ATGTGGCAAA	TGGTACTCT	GAACACTTTG	TTGAATTTGT	AAAAGATGTA	CGGAAGCGGT	780
TCCCCAGCA	CACCATCATG	GCAGGGAATG	TGTTAACAGG	AGAGATGGTA	GAAGAGCTCA	840
TCCCTTTCTG	GGCTGACATC	ATCAAAGTGG	GAATTGGGCC	AGGCTCTGTG	TGTACTACTC	900
GGAAGAAAAC	TGGAGTGGGG	TATCCACAGC	TCAGCGCAGT	GATGGAGTGT	GCAGATGCTG	960
CTCATGGCCT	CAAAGGCCAG	ATCATTTCAG	ATGAGGTTTG	CAGCTGTCTT	GGGGATGTGG	1020
CCAAGGCTTT	TGGGCGCAG	GCTGACTTCG	TGATGCTGGG	TGGCATCTGG	CTGGGCACA	1080
TGTAGTCAAG	TGGTGAGCTC	ATCAGAGGGG	ATGGCAAGAA	GTACAAGCTC	TTCTATGGAA	1140
GTAGTCTTGA	AATGGCCATG	AAGAAGTATG	CTGGGGGCTT	GGCTGAGTAC	AGAGCCTCAG	1200
AGGGAAGGAT	AGTGGAAAGT	CCTTTTAAAG	GAGATGTGGA	ACATAACCATC	CGAGACATCC	1260
TAGGAGGGAT	CCGCTCTACG	TGTACTATG	TGGGAGCAGC	TAACTCTCAA	GAGTTGAGCA	1320
GGAAGAACTAC	CTTCATCCGA	GTCAACCCAGC	AGGTGAATCC	AATCTTCAGT	GAGGCGTGCT	1380
AGACCTGAGC	AGTCTACCC	TCCCAGGCA	CCAGTACTCT	ACCATGGGGG	ATCCCAGATG	1440
GGGTCTCTAC	CCATCCCAGC	TACTGCAAGT	CTGTATTACT	TGTCTATTCT	CTGTCTCTCT	1500
ACTCTGAGG	GCTCCTGCAG	TAACTCTGTA	CTTCTCTATC	TGCACACACA	AAATGGCCAA	1560
GGCACTCACT	GGGAGGGAAG	CAAGGAAGCA	AACAGTCTGA	GGAAATGATG	CAAGAATAATC	1620
AAATGGGAAT	CTGGGGAGCC	AAACACAACAT	CCTGAAGATT	ATTAAGAAGA	TAAGATGCTG	1680
ATTGGTACAT	AAATCTTTTA	CATGGCCTTG	GTCTAGAGGA	GGCAGGCTTT	TAGAATCATG	1740
TTTTGTAAAT	CCGCTCACT	AAATGGGACC	TTACATATAC	TGAAAAGCTC	TGAAGTGTTT	1800
GTATATTTGA	AATACCTCAA	TAAAGAGAGA	GCTCATTGAC	TGT		1843

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 346 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 473772

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met	Arg	Ile	Glu	Glu	Asp	Leu	Lys	Leu	Gly	Phe	Lys	Asp	Val	Leu	Ile
1			5						10				15		
Arg	Pro	Lys	Arg	Ser	Thr	Leu	Lys	Ser	Arg	Ser	Asp	Val	Glu	Leu	Glu
		20						25				30			
Arg	Gln	Phe	Thr	Phe	Lys	His	Ser	Gly	Gln	Ser	Trp	Ser	Gly	Val	Pro
		35					40				45				
Ile	Ile	Ala	Ala	Asn	Met	Asp	Thr	Val	Gly	Thr	Phe	Ser	Met	Ala	Ser
		50				55				60					
Ala	Leu	Ala	Ser	Phe	Asp	Ile	Leu	Thr	Ala	Val	His	Lys	His	Tyr	Ser
		65			70				75					80	
Val	Glu	Glu	Trp	Gln	Ala	Phe	Ile	Asn	Asn	Ser	Ser	Ala	Asp	Val	Leu
		85						90					95		
Lys	His	Val	Met	Val	Ser	Thr	Gly	Thr	Ser	Asp	Ala	Asp	Phe	Glu	Lys
		100						105					110		

Thr Lys Gln Ile Leu Asp Leu Asn Pro Ala Leu Asn Phe Val Cys Ile
 115 120 125
 Asp Val Ala Asn Gly Tyr Ser Glu His Phe Val Gln Phe Val Ala Lys
 130 135 140
 Ala Arg Glu Ala Trp Pro Thr Lys Thr Ile Cys Ala Gly Asn Val Val
 145 150 155 160
 Thr Gly Glu Met Cys Glu Glu Leu Ile Leu Ser Gly Ala Asp Ile Val
 165 170 175
 Lys Val Gly Ile Gly Pro Gly Ser Val Cys Thr Thr Arg Val Lys Thr
 180 185 190
 Gly Val Gly Tyr Pro Gln Leu Ser Ala Val Ile Glu Cys Ala Asp Ala
 195 200 205
 Ala His Gly Leu Gly Gly Met Ile Val Ser Asp Gly Gly Cys Thr Thr
 210 215 220
 Pro Gly Asp Val Ala Lys Ala Phe Ala Arg Ala Asp Phe Val Met Leu
 225 230 235 240
 Gly Gly Met Leu Ala Gly His Glu Glu Ser Gly Gly Arg Ile Val Glu
 245 250 255
 Glu Asn Gly Glu Lys Phe Met Leu Phe Tyr Gly Met Ser Ser Glu Ser
 260 265 270
 Ala Met Lys Arg His Val Gly Gly Val Ala Glu Tyr Arg Ala Ala Glu
 275 280 285
 Gly Lys Thr Val Lys Leu Pro Leu Arg Gly Pro Val Glu Asn Thr Ala
 290 295 300
 Arg Asp Ile Leu Gly Gly Leu Arg Ser Ala Cys Thr Tyr Val Gly Ala
 305 310 315 320
 Ser Arg Leu Lys Glu Leu Thr Lys Arg Thr Thr Phe Ile Arg Val Gln
 325 330 335
 Glu Gln Glu Asn Arg Ile Phe Asn Asn Leu
 340 345

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 345 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 544455

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Pro Arg Ile Asp Ala Asp Leu Lys Leu Asp Phe Lys Asp Val Leu
 1 5 10 15
 Leu Arg Pro Lys Arg Ser Ser Leu Lys Ser Arg Ala Glu Val Asp Leu
 20 25 30
 Glu Arg Thr Phe Thr Phe Arg Asn Ser Lys Gln Thr Tyr Ser Gly Ile
 35 40 45
 Pro Ile Ile Val Ala Asn Met Asp Thr Val Gly Thr Phe Glu Met Ala
 50 55 60
 Ala Val Met Ser Gln His Ser Met Phe Thr Ala Ile His Lys His Tyr
 65 70 75 80
 Ser Leu Asp Asp Trp Lys Leu Phe Ala Thr Asn His Pro Glu Cys Leu
 85 90 95
 Gln Asn Val Ala Val Ser Ser Gly Ser Gly Gln Asn Asp Leu Glu Lys
 100 105 110
 Met Thr Ser Ile Leu Glu Ala Val Pro Gln Val Lys Phe Ile Cys Leu
 115 120 125

Asp	Val	Ala	Asn	Gly	Tyr	Ser	Glu	His	Phe	Val	Glu	Phe	Val	Lys	Leu
130						135					140				
Val	Arg	Ala	Lys	Phe	Pro	Glu	His	Thr	Ile	Met	Ala	Gly	Asn	Val	Val
145					150					155					160
Thr	Gly	Glu	Met	Val	Glu	Glu	Leu	Ile	Leu	Ser	Gly	Ala	Asp	Ile	Ile
				165					170					175	
Lys	Val	Gly	Val	Gly	Pro	Gly	Ser	Val	Cys	Thr	Thr	Arg	Thr	Lys	Thr
				180				185						190	
Gly	Val	Gly	Tyr	Pro	Gln	Leu	Ser	Ala	Val	Ile	Glu	Cys	Ala	Asp	Ser
		195					200					205			
Ala	His	Gly	Leu	Lys	Gly	His	Ile	Ile	Ser	Asp	Gly	Gly	Cys	Thr	Cys
		210				215					220				
Pro	Gly	Asp	Val	Ala	Lys	Ala	Phe	Gly	Ala	Gly	Ala	Asp	Phe	Val	Met
225					230					235					240
Leu	Gly	Gly	Met	Phe	Ser	Gly	His	Thr	Glu	Cys	Ala	Gly	Glu	Val	Phe
				245					250					255	
Glu	Arg	Asn	Gly	Arg	Lys	Leu	Lys	Leu	Phe	Tyr	Gly	Met	Ser	Ser	Asp
			260					265					270		
Thr	Ala	Met	Asn	Lys	His	Ala	Gly	Gly	Val	Ala	Glu	Tyr	Arg	Ala	Ser
		275					280					285			
Glu	Gly	Lys	Thr	Val	Glu	Val	Pro	Tyr	Lys	Gly	Asp	Val	Glu	Asn	Thr
		290				295				300					
Ile	Leu	Asp	Ile	Leu	Gly	Gly	Leu	Arg	Ser	Thr	Cys	Thr	Tyr	Val	Gly
305					310					315					320
Ala	Ala	Lys	Leu	Lys	Glu	Leu	Ser	Arg	Arg	Ala	Thr	Phe	Ile	Arg	Val
				325					330					335	
Thr	Gln	Gln	His	Asn	Thr	Val	Phe	Ser							
			340					345							

What is claimed is:

1. A substantially purified guanosine monophosphate reductase comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof.

2. An isolated and purified polynucleotide sequence encoding the guanosine monophosphate reductase of claim 1.

3. A polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of claim 2.

4. A hybridization probe comprising the polynucleotide sequence of claim 2.

5. An isolated and purified polynucleotide sequence comprising SEQ ID NO:2 or variants thereof.

6. A polynucleotide sequence which is complementary to the polynucleotide sequence of claim 2 or variants thereof.

7. A hybridization probe comprising the polynucleotide sequence of claim 6.

8. An expression vector containing the polynucleotide sequence of claim 2.

9. A host cell containing the vector of claim 8.

10. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 the method comprising the steps of:

a) culturing the host cell of claim 9 under conditions suitable for the expression of the polypeptide; and

- b) recovering the polypeptide from the host cell culture.

11. A pharmaceutical composition comprising a substantially purified guanosine monophosphate reductase having the amino acid sequence of claim 1 in conjunction with a
5 suitable pharmaceutical carrier.

12. A purified antibody which binds specifically to the polypeptide of claim 1.

13. A purified agonist which specifically binds to and modulates the activity of the
10 polypeptide of claim 1.

14. A purified antagonist which specifically binds to and modulates the activity of the polypeptide of claim 1.

15. A pharmaceutical composition comprising the purified antagonist of claim 14 in conjunction with a suitable pharmaceutical carrier.

16. A method for treating cancer comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 15.
20

17. A method for treating a viral disease comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 15.

18. A method for treating an inflammatory disease comprising administering to a
25 subject in need of such treatment an effective amount of the pharmaceutical composition of claim 15.

19. A method for treating an immunological disorder comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of

claim 15.

20. A method for detection of polynucleotides encoding guanosine monophosphate reductase in a biological sample comprising the steps of:

- 5 a) hybridizing the polynucleotide of claim 6 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and
- b) detecting said hybridization complex, wherein the presence of said complex correlates with the presence of a polynucleotide encoding guanosine monophosphate reductase in said biological sample.

10

ABSTRACT OF THE DISCLOSURE

5

The present invention provides a human guanosine monophosphate reductase (HGMPR) and polynucleotides which identify and encode HGMPR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGMPR and a method for producing HGMPR. The invention also provides for agonists, antibodies, or antagonists specifically binding HGMPR, and their use, in the prevention and treatment of diseases associated with expression of HGMPR. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGMPR for the treatment of diseases associated with the expression of HGMPR.

10

15 The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGMPR.

"Express Mail" mailing label number EM 081 942 611 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box Sequence, Washington, D.C. 20231 on 11/15/98

By:

Printed:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jennifer L. Hillman

Title: NOVEL GUANOSINE MONOPHOSPHATE REDUCTASE

Serial No.: To Be Assigned

Filing Date: Herewith

Examiner: Nashed, N.

Group Art Unit: 1814

Assistant Commissioner for Patents
Box Sequence
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Please consider and make of record the following remarks and amendments.

Please amend the application as follows:

IN THE SPECIFICATION

Page 3, line 6, delete "and 1C" and insert --1C, 1D and 1E--;

Page 3, line 13, delete "Figure 3" and insert --Figures 3A, 3B and 3C--;

Page 4, line 17, delete “represent” and insert --represents--;

Page 7, line 5, delete “hydrogen binds” and insert --hydrogen bonds--;

Page 7, line 15, delete “for the sequence” and insert --the sequence--;

Page 10, line 21, delete "chromosomes" and insert --chromosome--;

Page 11, line 25, delete "E coli" and insert --E. coli--;

Page 12, line 1, delete "E coli" and insert --E. coli--;

Page 13, line 29, delete "threonine" and insert --threonine and--;

Page 15, line 27, delete "devise" and insert --device--;

Page 21, line 20, delete "which confer" and insert --which confers--;

Page 21, line 29, delete "55:121-131).. " and insert --55:121-131)--;

Page 23, line 22, delete "sequence" and insert --sequences--;

Page 24, line 9, delete "Merrifield" and insert --(Merrifield--;

Page 34, line 19, delete "formation" and insert --formation.--;

Page 34, line 21, delete "photometric," and insert --photometric--;

Page 37, line 27, delete "techniques.," and insert --techniques.--;

Page 38, line 7, delete "disease ," and insert --disease.--;

Page 38, line 14, delete "as mouse" and insert --as a mouse--.

IN THE CLAIMS

11. (Amended) A pharmaceutical composition comprising a substantially purified guanosine monophosphate reductase having the amino acid sequence of [claim 1] SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.

12. (Amended) A purified antibody which binds specifically to the polypeptide of [claim 1] amino acid sequence of SEQ ID NO:1.

13. (Amended) A purified agonist which specifically binds to and modulates the activity of the [polypeptide of claim 1] amino acid sequence of SEQ ID NO:1.

14. (Amended) A purified antagonist which specifically binds to and modulates the

activity of the [polypeptide of claim 1] amino acid sequence of SEQ ID NO:1.

REMARKS

No new matter has been added by these amendments. Applicants respectfully request entry of the present amendment.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date: 1/12/98

Lucy J. Billings
Lucy J. Billings
Reg. No. 36,749

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

5'	9	18	27	36	45	54
NGT	AAA TCA GCC TCT TGC CCC ATT	GCT CTT TGC AGG GGT AGA AGA AGG AAG TGT				
	63	72	81	90	99	108
AGC	GGG GTA AGG AAT GCA CCG TCA	GGG TCT CTC ACA ACC CTT TCC CAG CTC TCC				
	117	126	135	144	153	162
TCC	CCA ACA AAC AGT ACC TGG GAT	GGA GCC CTA GGG TAA TCG CAG CCA CGG GAT				
	171	180	189	198	207	216
GGG	TCG AGG TGA CAG GCT TCA GGG	ACC ACA CTT CGG CCT TTG CCC GAC CTT CCA				
	225	234	243	252	261	270
CAA	CTT AAG CGA AGA GAG GCC ACC	AGC CGT AAC AGG GCG TTA AAG CCC AGG GGA				
	279	288	297	306	315	324
AGA	TTG GTC CTT ATG ACT TGC TGC	CTT CCA GCC CTC AGA TTC ATC GCT ACC CCG				
		M T C C	L P A L R F	I A T P		
	333	342	351	360	369	378
AGG	CTA AGC GCC ATG CCT CAT ATT	GAC AAC GAT GTG AAA CTG GAC TTC AAG GAT				
R	L S A M P H I D N D V K L D F K D					
	387	396	405	414	423	432
GTC	CTT TTG AGG CCC AAA CGC AGT	ACC CTT AAG TCT CGA AGT GAG GTG GAT CTC				
V	L L R P K R S T L K S R S E V D L					
	441	450	459	468	477	486
ACA	AGA TCC TTT TCA TTT CGG AAC	TCA AAG CAG ACA TAC TCT GGG GTT CCC ATC				
T	R S F S F R N S K Q T Y S G V P I					
	495	504	513	522	531	540
ATT	GCT GCC AAT ATG GAT ACT GTG	GGC ACC TTT GAG ATG GCC AAG GTT CTC TGT				
I	A A N M D T V G T F E M A K V L C					
	549	558	567	576	585	594
AAG	TTC TCT CTC TTC ACT GCT GTC	CAT AAG CAC TAT AGC CTC GTT CAG TGG CAA				
K	F S L F T A V H K H Y S L V Q W Q					
	603	612	621	630	639	648
GAG	TTT GCT GGC CAG AAT CCT GAC	TGT CTT GAG CAT CTG GCT GCC AGC TCA GGC				
E	F A G Q N P D C L E H L A A S S G					
	657	666	675	684	693	702
ACA	GGC TCT TCT GAC TTT GAG CAG	ATC CTG GAA CAG ATC CTG GAA GCT ATT CCC CAG				
T	G S S S D F E Q L E Q I L E A I P Q					

FIGURE 1A

-	711	720	729	738	747	756
GTG AAG TAT ATA TGC CTG GAT GTG GCA AAT GGC TAC TCT GAA CAC TTT GTT GAA						
V K Y I C L D V A N G Y S E H F V E						
765	774	783	792	801	810	
TTT GTA AAA GAT GTA CGG AAG CGC TTC CCC CAG CAC ACC ATC ATG GCA GGG AAT						
F V K D V R K R F P Q H T I M A G N						
819	828	837	846	855	864	
GTG GTA ACA GGA GAG ATG GTA GAA GAG CTC ATC CTT TCT GGG GCT GAC ATC ATC						
V V T G E M V E E L I L S G A D I I						
873	882	891	900	909	918	
AAA GTG GGA ATT GGG CCA GGC TCT GTG TGT ACT ACT CGG AAG AAA ACT GGA GTG						
K V G I G P G S V C T T R K K T G V						
927	936	945	954	963	972	
GGG TAT CCA CAG CTC AGC GCA GTG GAG TGT GCA GAT GCT GCT CAT GGC CTC						
G Y P Q L S A V M E C A D A A H G L						
981	990	999	1008	1017	1026	
AAA GGC CAC ATC ATT TCA GAT GGA GGT TGC AGC TGT CCT GGG GAT GTG GCC AAG						
K G H I I S D G G C S C P G D V A K						
1035	1044	1053	1062	1071	1080	
GCT TTT GGG GCA GGA GCT GAC TTC GTG ATG CTG GGT GGC ATG CTG GCT GGG CAC						
A F G A G A D F V M L G G M L A G H						
1089	1098	1107	1116	1125	1134	
AGT GAG TCA GGT GGT GAG CTC ATC GAG AGG GAT GGC AAG AAG TAC AAG CTC TTC						
S E S G G E L I E R D G K K Y K L F						
1143	1152	1161	1170	1179	1188	
TAT GGA ATG AGT TCT GAA ATG GCC ATG AAG AAG TAT GCT GGG GGC GTG GCT GAG						
Y G M S S E M A M K K Y A G G V A E						
1197	1206	1215	1224	1233	1242	
TAC AGA GCC TCA GAG GGA AAG ACA GTG GAA GTT CCT TTT AAA GGA GAT GTG GAA						
Y R A S E G K T V E V P F K G D V E						
1251	1260	1269	1278	1287	1296	
CAT ACC ATC CGA GAC ATC CTA GGA GGG ATC CGC TCT ACG TGT ACC TAT GTG GGA						
H T I R D I L G G I R S T C T Y V G						
1305	1314	1323	1332	1341	1350	
GCA GCT AAG CTC AAA GAG TTG AGC AGG AGA ACT ACC TTC ATC CGA GTC ACC CAG						
A A K L K E L S R R T T F I R V T Q						
1359	1368	1377	1386	1395	1404	
CAG GTG AAT CCA ATC TTC AGT GAG GCG TGC TAG ACC TGA GCA GTT CTA CCC TCC						
Q V N P I F S E A C						

FIGURE 1B

1413 1422 1431 1440 1449 1458
 CAA GGC ACC AGT ACT CTA CCA TGG GGC ATC CCA AGT GGG GTC CTC ACC CAT CCC

1467 1476 1485 1494 1503 1512
 AGC TAC TGC AGC TCT GTA TTA CTT TGT CAT TTC CTG TTG TCT CAC TCC TGA GGG

1521 1530 1539 1548 1557 1566
 CTC CTG CAG TAA CTC TGT ACT TCT CTA TCT GCA CAC ACA AAA TGC CCA AGG CAC

1575 1584 1593 1602 1611 1620
 TCA CTG GGG AGG AAG CAA GGA AGC AAA CAG TCT GAG GAA ATG ATG CAA GAA AAT

1629 1638 1647 1656 1665 1674
 CAA ATG GGA ATC TGG GGA CCC AAC ACA ACA TCC TGA AGA TTA TTA AAA GGA AAA

1683 1692 1701 1710 1719 1728
 GAT GCT GAT TGG TAC ATA AAT CTT TTA CAT GGC CTT GGT CTA GAG GAG GCA GGC

1737 1746 1755 1764 1773 1782
 TTT TAG AAT CAT GTT TTG TTA ATC CGC TTC ACT AAA TTG GAC CTT CAC ATA TCT

1791 1800 1809 1818 1827 1836
 AAA AAG CTC TGA AGT GTT TGT ATA TTT GAA ATA CCT CAA TAA AGA GAG AGC TCA

TTG ACT GT 3'

FIGURE 1C

1 MTCCLPALRFIATPRLSAMPHIIDDVKLD^{H2MR}DFKDVLLRPKRS
 1 M-----⁹⁶⁷³⁷⁷²
 1 M-----⁹⁵⁴⁴⁴⁵⁵
 1 M-----PRIDADLKLD^{H2MR}DFKDVLLRPKRS
 21 TLKSRSEVDILRSFSEFRNSKQTYSGVPPIAANMDTVGTFE
 22 TLKSRSDVGLERQFTFKHSGOSMSGVPPIAANMDTVGTFS
 23 SLKSRNAEVDLERTFEFRNSKQTYSGIPILIVANMDTVGTFE
 24 ⁹⁵⁴⁴⁴⁵⁵
 25 MAKVLCKFSLFTAVHKHYSLVQWQEFAGQNDP-DCLEHLA^{H2MR}
 26 MASALASEDILTA^{H2MR}VHKHYSVEEWQAFIINSSADVLKHVMV
 27 MALVMSOHSWFTATHKHYSLDDMKLEFATNHP-ECLQONVAV
 28 ⁹⁵⁴⁴⁴⁵⁵
 29 SSGTGSSDFEQLEQILEAIPOVKYICLDVANGYSEHFVEF
 30 SSGTGSSDFEQLEQILEAIPOVKYICLDVANGYSEHFVEF
 31 SSGTGSSDFEQLEQILEAIPOVKYICLDVANGYSEHFVEF
 32 SSGTGSSDFEQLEQILEAIPOVKYICLDVANGYSEHFVEF
 33 SSGTGSSDFEQLEQILEAIPOVKYICLDVANGYSEHFVEF
 34 ⁹⁵⁴⁴⁴⁵⁵
 35 VKDVRKREPQHTIMAGNVVTGEMVEELILSGADIIKVGIG
 36 VKDVRKREPQHTIMAGNVVTGEMVEELILSGADIIKVGIG
 37 VKDVRKREPQHTIMAGNVVTGEMVEELILSGADIIKVGIG
 38 VKDVRKREPQHTIMAGNVVTGEMVEELILSGADIIKVGIG
 39 ⁹⁵⁴⁴⁴⁵⁵
 40 PGSVCTTRKKTGVGYPQLSAVMECADAHGLKGHIISDGG
 41 PGSVCTTRKKTGVGYPQLSAVMECADAHGLKGHIISDGG
 42 PGSVCTTRKKTGVGYPQLSAVMECADAHGLKGHIISDGG
 43 PGSVCTTRKKTGVGYPQLSAVMECADAHGLKGHIISDGG
 44 ⁹⁵⁴⁴⁴⁵⁵
 45 CTCPGDVAKAFAGAGADFVMLGGMFSGHTECAGEVFIERNGR
 46 CTCPGDVAKAFAGAGADFVMLGGMFSGHTECAGEVFIERNGR
 47 CTCPGDVAKAFAGAGADFVMLGGMFSGHTECAGEVFIERNGR
 48 CTCPGDVAKAFAGAGADFVMLGGMFSGHTECAGEVFIERNGR
 49 ⁹⁵⁴⁴⁴⁵⁵

FIGURE 2A

260	R	X	K	L	F	Y	G	M	S	S	E	M	A	M	K	K	Y	A	G	G	V	A	E	Y	R	A	S	E	G	K	T	V	E	V	F	K	G	D	V	H3MR	
261	R	F	M	L	F	Y	G	M	S	S	E	S	A	M	K	R	H	V	G	G	V	A	E	Y	R	A	A	E	G	K	T	V	K	L	P	L	R	G	E	V	9473772
262	R	L	K	L	F	Y	G	M	S	S	D	T	A	M	N	K	H	A	G	G	V	A	E	Y	R	A	S	E	G	K	T	V	E	V	F	Y	K	G	D	V	9544455
320	E	H	T	I	R	D	I	L	G	G	L	R	S	T	C	T	Y	V	G	A	A	K	L	K	E	L	S	R	R	T	T	F	I	R	V	T	O	V	N	H3MR	
301	E	N	T	A	R	D	I	L	G	G	L	R	S	A	C	T	Y	V	G	A	S	R	L	K	E	L	T	R	T	T	F	I	R	V	O	E	O	E	N	9473772	
302	E	N	T	I	L	D	I	L	G	G	L	R	S	T	C	T	Y	V	G	A	A	K	L	K	E	L	S	R	R	A	T	T	F	I	R	V	T	O	H	N	9544455
360	P	I	F	S	E	A	C																																	H3MR	
341	R	L	F	N	N	L																																9473772			
342	T	V	F	S																																	9544455				

FIGURE 2B

FIGURE 3B




FIGURE 3C

Library	Lib Description	Abun	Pct Abun
MMLR3DT01	macrophages (adher PBMNC), M/F, 72-hr MLR	1	0.0332
ENDCNOT03	endothelial cells, dermal microvascular, neonatal M	1	0.0210
LUNGFEM01	lung, fetal, NORM, WM	1	0.0148
PROSTUT04	prostate tumor, 57 M, match to PROSNOT06	1	0.0117
BRAINOT09	brain, fetal M	1	0.0093
BRAITUT02	brain tumor, metastasis, 58 M	1	0.0075

FIGURE 4

**DECLARATION AND POWER OF ATTORNEY FOR
UNITED STATES PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

A NOVEL GUANOSINE MONOPHOSPHATE REDUCTASE

the specification of which:

 / is attached hereto.

 X / was filed on December 26, 1996, as application Serial No. 08/774,169 and if this box contains an X /, was amended on _____.

 / was filed as Patent Cooperation Treaty international application No. _____ on _____, 19____, if this box contains an X /, was amended on under Patent Cooperation Treaty Article 19 on _____, 19____, and if this box contains an X /, was amended on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge my duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under Title 35, United States Code, §119 or §365(a)-(b) of any foreign application(s) for patent or inventor's certificate indicated below and of any Patent Cooperation Treaty international applications(s) designating at least one country other than the United States indicated below and have also identified below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application for said subject matter the priority of which is claimed:

Country	Number	Filing Date	Priority Claimed
_____	_____	_____	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application Serial No.	Filed	Status (Pending, Abandoned, Patented)
_____	_____	_____

I hereby appoint the following:

LUCY J. BILLINGS
MICHAEL C. CERRONE

Registration No. 36,749
Registration No. 39,132

respectively and individually, as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

LUCY J. BILLINGS, ESQ.
INCYTE PHARMACEUTICALS, INC.
3174 PORTER DRIVE, PALO ALTO, CA 94304


TEL: 415-855-0555 FAX: 415-845-4166

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

***IMPORTANT:** Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

**Sole Inventor or
First Joint Inventor:**

Full name: **JENNIFER L. HILLMAN**
Signature: 
Date: May 14, 1997
Citizenship: United States of America
Residence: San Jose, California
P.O. Address: 467 N. Third Street, #3
San Jose, CA 95112